Top Story

Decreased hemoglobin levels did not impact SVR rate in patients treated for HCV genotype 1

October 22, 2014

PHILADELPHIA — Decreased hemoglobin levels were well-managed in patients with hepatitis C virus infection receiving a three direct-acting antiviral regimen with or without ribavirin and did not affect response to treatment, according to data presented at the ACG Annual Scientific Meeting.

Vinod Rustgi, MD, of Metropolitan Research, Fairfax, Virginia, and colleagues analyzed pooled data from treatment naïve and treatment-experienced patients with HCV genotype 1a or 1b (n=910) enrolled in the PEARL-II (n=186), III (n=419) and IV (305) phase 3 trials undergoing treatment with a three direct-acting antiviral (3D) regimen. Patients were assigned ABT-450/ritonavir/ombitasvir (150 mg/100 mg/25 mg once daily) and dasabuvir (250 mg twice daily) with (n=724) or without ribavirin (RBV; n=186) for 12 weeks. Hemoglobin levels were evaluated at baseline, throughout therapy and follow-up to determine any decreases and effects on treatment.

HCV nucleotide analogue polymerase inhibitor associated with cardiac dysfunction

October 20, 2014
Fourteen of 34 patients with hepatitis C virus infection who were treated with the novel nucleotide analogue polymerase inhibitor BMS-986094 had some evidence of cardiac…
In the Journals

SVR after therapy reduced inflammation, fibrosis in HCV patients

October 17, 2014
In a new study, patients with chronic hepatitis C virus infection who achieved a sustained virologic response with interferon-based therapy experienced decreases in…
In the Journals

Polymorphisms increased risk for steatosis in patients with HCV genotype 1

October 15, 2014
Phospholipase domain containing 3, or PNPLA3, polymorphism was a predictor for steatosis among Spanish patients with hepatitis C virus genotype 1 infection, according to…
CME
figure

HCV Consults: Volume 1, Number 1

This activity is supported by educational grants from AbbVie and Genentech.

Physicians seldom experience a paradigm shift in disease management as great as that transpiring in HCV therapy. With…
More »
Meeting News Coverage Video
figure

Tenofovir/entecavir recommended for HBV patients with malignancy

May 16, 2014
CHICAGO — Spilios Manolakopoulos, MD, of the internal medicine and hepatology departments at…
More »
CME
figure

CRITICAL ISSUES IN HBV: Considerations in Optimizing HBV Treatment

This activity is supported by an educational grant from Gilead Sciences Medical Affairs.

Hepatitis B virus (HBV) infection is a global epidemic with a worldwide burden. Physicians must address the importance…
More »

Filter By:

figure Meeting News Coverage

Decreased hemoglobin levels did not impact SVR rate in patients treated for HCV genotype 1

October 22, 2014
PHILADELPHIA — Decreased hemoglobin levels were well-managed in patients with hepatitis C virus infection receiving a three direct-acting…

HCV nucleotide analogue polymerase inhibitor associated with cardiac dysfunction

October 20, 2014
Fourteen of 34 patients with hepatitis C virus infection who were treated with the novel nucleotide analogue polymerase inhibitor BMS-986094 had some…
In the Journals

SVR after therapy reduced inflammation, fibrosis in HCV patients

October 17, 2014
In a new study, patients with chronic hepatitis C virus infection who achieved a sustained virologic response with interferon-based therapy…
In the Journals

Polymorphisms increased risk for steatosis in patients with HCV genotype 1

October 15, 2014
Phospholipase domain containing 3, or PNPLA3, polymorphism was a predictor for steatosis among Spanish patients with hepatitis C virus genotype 1…
FDA News Perspective

FDA approves Harvoni for HCV treatment

October 10, 2014
Using the breakthrough therapy designation, the FDA approved the first combination pill for treatment of chronic hepatitis C virus genotype 1 that…
figure In the Journals

Spontaneous HBeAg seroclearance increased chances for HBsAg seroclearance

October 8, 2014
Patients with chronic hepatitis B virus infection and positive for the hepatitis B e antigen had a greater chance of hepatitis B surface antigen…
In the Journals

HEV antibody prevalence decreased in Germany across 15 years

October 2, 2014
Prevalence of anti-hepatitis E virus infection declined in southeastern Germany by more than 15% from 1996 to 2011, according to new study data.Serum…
figure

Top HCV studies presented at ICAAC

September 26, 2014
Healio.com/Hepatology has compiled a list of the latest, most relevant research on hepatitis C virus infection presented recently at ICAAC 2014 in…

EMA committee recommends Harvoni to treat HCV

September 26, 2014
The European Medicines Agency’s Committee for Medicinal Products for Human Use recommends a marketing authorization application for…
figure

St. Louis University to test sofosbuvir/ribavirin in pediatric HCV cases

September 23, 2014
Researchers at Saint Louis University will begin study enrollment to test the safety and efficacy of sofosbuvir with ribavirin to treat hepatitis C…
More Headlines »